Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
Site US10021, Phoenix, Arizona, United States
Site US10004, Beverly Hills, California, United States
Site US10030, McAllen, Texas, United States
East Florida Eye Institute, Stuart, Florida, United States
Associated Retinal Consultants, Royal Oak, Michigan, United States
St Eriks Eye Hospital, Stockholm, Sweden
Novartis Investigative Site, Chemnitz, Germany
Toronto Western Hospital, Toronto, Ontario, Canada
Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, Cambridgeshire, United Kingdom
Colchester Hospital University NHS Foundation Trust, Colchester, Essex, United Kingdom
Ashford & St Peters Hospitals NHS Foundation Trust, Chertsey, Surrey, United Kingdom
Nihon University Hospital, Chiyoda-ku,Tokyo, Japan
1 Fukushima Medical University, Fukushima-shi, Japan
Kyushu University Hospital, Kita-ku, Fukuoka-shi Fukuoka, Japan
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.